Artiva Biotherapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ARTV Nasdaq 2836 www.artivabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Artiva Biotherapeutics, Inc.

Sector Update: Healthcare Stocks Decline Late Afternoon - Oct 27th, 2026 1:51 pm
Artiva Biotherapeutics Plunges Into Crisis Over Patient Deaths and Possible Liquidation - Oct 27th, 2026 11:58 am
Why Is Artiva Biotherapeutics Discontinuing AlloNK Development and Cutting 94% of Its Workforce? - Oct 27th, 2026 10:22 am
Artiva to quit autoimmune cell therapy work, cut staff after patient deaths - Oct 27th, 2026 9:44 am
Artiva Scraps Development Of Lead Drug Candidate After Patient Deaths — ARTV Stock Heads For Worst Session In Over 18 Months - Oct 27th, 2026 8:08 am
Artiva Biotherapeutics stock tumbles after halting drug trial - Oct 27th, 2026 6:40 am
Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK® - Oct 27th, 2026 5:30 am
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026 - Oct 2nd, 2026 7:05 am
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026) - Oct 1st, 2026 5:30 am
Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease - Sep 23rd, 2026 5:30 am
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum - Sep 17th, 2026 6:00 am
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026 - Sep 8th, 2026 5:30 am
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September - Sep 2nd, 2026 6:30 am
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Aug 6th, 2026 2:05 pm
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jul 17th, 2026 5:30 am
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year? - Jul 8th, 2026 7:40 am
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - Jun 23rd, 2026 2:05 pm
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today - Jun 8th, 2026 4:30 am
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - May 28th, 2026 6:00 am